Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has selected TIBCO Software Inc. (NASDAQ: TIBX) to enhance its suite of eClinical service offerings, incorporating industry leading enterprise infrastructure software, TIBCO ActiveMatrix BusinessWorks™, as well as TIBCO Enterprise Message Service™, into its eClinical platform. The TIBCO solution provides seamless integration of software applications and enhanced real-time data exchange capabilities across Perceptive's eClinical Suite to help its customers make more effective decisions about their clinical development programs.
The new capabilities bring further performance improvements to Perceptive's eClinical platform, powered by industry-leading foundational technologies, including reporting, integration, and identity management solutions, which enable applications of its eClinical Suite. The TIBCO solution will enable Perceptive to provide its customers with improved application integration efficiency, with greater standardization and reduced implementation timeframes.
"Customers are increasingly seeking highly integrated eClinical solutions in contrast to using standalone applications. Our integrated solutions allow for real-time data interchange and the ability for diverse applications to work synergistically," said Nicholas Richards, Vice President, Product Development, Perceptive Informatics. "We are focused on providing a single integration platform to accelerate the clinical development process. To assist customers in identifying and implementing clinical trial process improvements, Perceptive is committed to bringing further enhancements to our sophisticated enterprise platform, which incorporates technologies such as those from TIBCO."
TIBCO ActiveMatrix BusinessWorks™ brings enhanced capabilities to Perceptive's common framework for integrating and synchronizing systems and web-based services. In combining TIBCO's leading orchestration and integration technologies with its extensive experience, Perceptive is delivering hundreds of solutions integrations for its customers to help improve data quality, streamline workflow, and enable a fully standardized integration process.
The eClinical Suite from Perceptive Informatics provides advanced integration and interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS), the Medical Imaging tracking application, the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies. The Suite supports real-time data interchange and enables diverse applications to work synergistically. For more information about Perceptive's eClinical Suite visit: www.perceptive.com/Solutions/eClinical-Suite.html.
# # #
TIBCO Software Inc. (NASDAQ: TIBX) is a provider of infrastructure software for companies to use on-premise or as part of cloud computing environments. Whether it's optimizing claims, processing trades, cross-selling products based on real-time customer behavior, or averting a crisis before it happens, TIBCO provides companies the two-second advantageTM – the ability to capture the right information at the right time and act on it preemptively for a competitive advantage. More than 4,000 customers worldwide rely on TIBCO to manage information, decisions, processes and applications in real time. Learn more at www.tibco.com.
TIBCO, TIBCO Software, and TIBCO ActiveMatrix BusinessWorks , TIBCO Enterprise Message Service, and Two-Second Advantage are trademarks or registered trademarks of TIBCO Software Inc. or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 10,170 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 9, 2010, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.